Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
02235 MICROTECH MED-B
8.650-0.380-4.21%
Closed
02/03 16:08 CCT
High
8.900
Open
8.900
Turnover
5.67M
Low
7.930
Pre Close
9.030
Volume
629.80K
Price Forecast
News
Comment
Weitai Medical-B: interim report 2022
Weitai Medical-B: interim results announcement for the six months ended June 30, 2022
Weitai Medical-B: annual report 2021
Weitai Medical-B: annual results announcement for the year ended December 31, 2021
Weitai Medical-B: date of the board of directors
Weitai Medical (02235.HK) was selected as a provincial-level "specialized and special new" small and medium-sized enterprise.
Weitai Medical-B (02235.HK) announced that the company was identified as a provincial-level "specialized and special new" small and medium-sized enterprise in Zhejiang Province in 2021. For a period of three years from December 2021. Selected into the provincial "specialized and special new" small and medium-sized enterprises, the company will become the key service enterprises of the government's economic and credit departments, obtain more resources and policy support, and enhance the company's market competitiveness in the fields of diabetes monitoring, treatment and management. (de/d) ~
Weitai Medical-B [02235] is now trading at HK $20.25, a decrease of 13.28%.
Phoenix New Media Hong Kong shares | as of 11:35, Weitai Medical-B [02235] was quoted at HK $20.25,3.1 or 13.28% lower than yesterday's closing price of HK $23.35. the turnover was HK $67900, with a high price of HK $23.05 today and a lowest price of HK $20.25. based on yesterday's closing price, the 10-day average price is HK $24.52, the 50-day average price is HK $27.69, and the current price-to-earnings ratio is 0.00 times earnings. The 14-day strength index was 36.02.
Weitai Medical-B [02235] is now trading at HK $26.95, an increase of 14.68%.
Phoenix New Media Hong Kong shares | as of 10:39, Weitai Medical-B [02235] was at HK $26.95, an increase of HK $3.45 or 14.68% compared with yesterday's closing price of HK $23.50, with a turnover of HK $561600, with a high price of HK $26.95 today and a lowest price of HK $22.50. according to yesterday's closing price, the 10-day average price is HK $25.22, the 50-day average price is HK $27.94, and the current price-to-earnings ratio is 0.00 times earnings. The 14-day strength index was 29.02.
Weitai Medical-B [02235] is now at HK $22.25, a decrease of 10.82%.
Phoenix New Media Hong Kong shares | as of 13:58, Weitai Medical-B [02235] was at HK $22.25, down HK $2.70 or 10.82% from yesterday's closing price, with a turnover of HK $628400, with a high price of HK $24.50 today and a lowest price of HK $22.25. according to yesterday's closing price, the 10-day average price is HK $26.56, the 50-day average price is HK $0.00, and the current price-to-earnings ratio is 0.00 times earnings. The 14-day strength index was 33.33.
Weitai Medical-B (02235.HK) receives shareholder Shi Yi to increase its stake in 323200 shares
According to the latest equity disclosure information of the Stock Exchange, Weitai Medical-B (02235.HK) received shareholder Shi Yi to increase its holdings of 323200 shares at an average price of HK $27.00 per share, involving a capital of about HK $8.7264 million, according to the latest equity disclosure information of the Stock Exchange. After the increase, Shi Yi's latest number of shares is 3528100 shares, rising from 4.87 per cent to 5.36 per cent.
Company Overview
More
Weitai Medical Devices (Hangzhou) Co., Ltd. is a pioneer in the field of medical devices for diabetes management. Through innovation and integration of diabetes treatment and monitoring technology, Weitai Medical Devices (Hangzhou) Co., Ltd. has been able to reshape a new model of diabetes management in China and around the world. The company was founded in 2011 and is headquartered in Zhejiang Overseas High-Level Talent Innovation Park - Hangzhou Future Science and Technology City. It has been designated as a key enterprise research center for diabetes treatment devices in Zhejiang Province, China, and has also established a R&D center in Silicon Valley. Weitai Healthcare has a strong in-house R&D team of nearly 100 members, including academics, scientists, elite engineers and experienced experts from world-renowned universities. More than 30% of R&D members have master's or doctorate degrees. Our main R&D personnel have an average of 13 years of relevant R&D experience, of which more than a dozen have worked for top medical device companies.
Weitai Medical focuses on technological innovation in the field of medical devices for diabetes management, and is committed to promoting the company's products to the global market. Currently, the company's main products include:
Treatment products
Equil submersible insulin pump system
Diagnostic products
AIDEX Dynamic Blood Glucose Monitoring System (CGMS)
Various blood sugar monitoring systems (BGMS)
As we all know about POCT products, diabetics face many problems in their lives, and a series of products produced by Weitai Medical have brought them a free and flexible experience, and also given them more choices in their lives.
CEO： Pan Zheng
Market： Hong Kong motherboard
Listing Date： 10/19/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet